ASTS
AST SpaceMobile, Inc.
ASTS has a slight edge over DOX overall, supported by stronger modeled upside and stronger fundamentals.
DOX
Amdocs Limited
DOX has lower modeled downside risk, despite its lower overall score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
DOX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
DOX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
DOX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.1x | $44.11 | — |
| Current | 11x | $44.11 | — |
| Cheap | 14x | $60.81 | +38% |
| Fair | 18x | $76.51 | +73% |
| Expensive | 20x | $85.23 | +93% |
Historical ranges are pointers, not guarantees.
DOX's PE is in its cheap range at 11x. On analysts' estimates for next year's earnings, today's price would be 8.1x.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
DOX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong decline | |
| Decline | |
| Weakening | |
| Limited | |
| Low |
Analysts expect DOX's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
DOX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.47 | +30% |
| Q2 2026 | $4.20 | -14% |
| Q1 2026 | $5.00 | +5.9% |
| Q4 2025 | $5.17 | +21% |
| Q3 2025 | $5.05 | +20% |
| Q2 2025 | $4.90 | +13% |
| Q1 2025 | $4.72 | +6.1% |
| Q4 2024 | $4.28 | -8.4% |
| Q3 2024 | $4.21 | -6% |
DOX has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over DOX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
DOX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.2B | +2.7% |
| Q1 2026 | $1.2B | +3.9% |
| Q4 2025 | $1.2B | +4.1% |
| Q3 2025 | $1.2B | -9% |
| Q2 2025 | $1.1B | -8.4% |
| Q1 2025 | $1.1B | -9.4% |
| Q4 2024 | $1.1B | -11% |
| Q3 2024 | $1.3B | +1.7% |
DOX's revenue grew through 2021 and has held roughly level since: $1.2B last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | +0.3 points |
| Q1 2026 | 16% | -1.1 points |
| Q4 2025 | 18% | 0 points |
| Q3 2025 | 18% | +9 points |
| Q2 2025 | 18% | +3.6 points |
| Q1 2025 | 18% | +5 points |
| Q4 2024 | 18% | +3.1 points |
| Q3 2024 | 8.9% | -2.3 points |
DOX has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
DOX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $171.9M | -19% |
| Q1 2026 | $80.3M | -49% |
| Q4 2025 | $187.9M | +140% |
| Q3 2025 | $198.6M | +3.4% |
| Q2 2025 | $211.8M | +21% |
| Q1 2025 | $156.5M | +38% |
| Q4 2024 | $78.2M | -44% |
| Q3 2024 | $192.1M | -22% |
DOX has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
DOX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -1.8M shares |
| 1 year | -4.9% | -5.5M shares |
| 3 years | -12% | -14.7M shares |
| 5 years | -17% | -22.4M shares |
| Available history | -22% | -30.5M shares |
DOX has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $142.6M |
| Q1 2026 | $138.3M |
| Q4 2025 | $146.2M |
| Q3 2025 | $136.4M |
| Q2 2025 | $135.2M |
| Q1 2025 | $135.2M |
| Q4 2024 | $144.5M |
| Q3 2024 | $119.8M |
DOX spent $563M buying back its own shares over the past year, up 5.4% from the year before.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DOX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
| Q3 2024 | 0.6x | Very low |
DOX's net debt is about a year of its operating earnings (EBITDA), up from less than a year a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
DOX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 36.7 | Neutral |
DOX's weekly RSI is 30 (neutral) and its Stochastic is 37 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
DOX PE vs Technology Sector
| Metric | DOX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 62% below |
| PE % | 2 | 35 | 33 pts below |
DOX is trading at 11x earnings, a 62% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over DOX on trend strength, trading above more of its moving averages.
DOX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $55.8 | 21% below |
| 20 week MA | $56.7 | 22% below |
| 50 week MA | $64.2 | 31% below |
| 100 week MA | $75.3 | 41% below |
| 200 week MA | $81.7 | 46% below |
DOX is in a downtrend: it's below all five of its weekly moving averages, and 46% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
DOX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.6 | $69.7 | -4.1% |
| 2021 | $69.7 | $74.3 | +6.7% |
| 2022 | $74.3 | $89.4 | +20% |
| 2023 | $89.4 | $87.9 | -1.6% |
| 2024 | $87.9 | $85.8 | -2.4% |
| 2025 | $85.8 | $81.7 | -4.7% |
| 2026 YTD | $81.7 | $44.1 | -46% |
DOX has the edge over ASTS on returns for 2026, with the stronger performance.